Showing 511-520 of 3239 results for "".
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Use of Personal Care Products During Pregnancy Linked to Adverse Effects in Newbornshttps://practicaldermatology.com/news/use-of-personal-care-products-during-pregnancy-linked-to-adverse-effects-in-newborns/2458575/Personal care products used during pregnancy may be linked to adverse reproductive effects in newborns, report researchers from SUNY Downstate Medical Center’s School of Public Health. The long-term consequences of this are not clear and the findings must be reproduced in larg
- New Case Study Highlights Black Henna Tattoo Riskshttps://practicaldermatology.com/news/new-case-study-highlights-black-henna-tattoo-risks/2458573/Black henna tattoos should be avoided, especially during foreign travel, UK doctors warn in BMJ Case Reports. Researchers from the University of Sheffiel
- Modernizing Medicine's Dermatology-specific EHR System Top Rated by KLAShttps://practicaldermatology.com/news/modernizing-medicines-dermatology-specific-ehr-system-top-rated-by-klas/2458591/Modernizing Medicine, Inc.’s EMA Dermatology has been rated the top electronic health record (EHR) system for dermatologists in the inaugural KLAS “Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report.” KLAS, best known for its “Best in KLAS: Soft
- New MRF White Paper Provides Road Map for Eradicating Melanomahttps://practicaldermatology.com/news/new-mrf-white-paper-provides-road-map-for-eradicating-melanoma/2458604/More research needs to be done about what range of wavelengths in the ultraviolet band need to be blocked to prevent melanoma, according to a new white paper from Melanoma Research Foundation (MRF). The paper, "The Stat
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- Medical Professionals, Practical Dermatology® Board Members, Recognized for Outstanding Work in Psoriatic Disease Fieldhttps://practicaldermatology.com/news/medical-professionals-practical-dermatology-board-members-recognized-for-outstanding-work-in-psoriatic-disease-field/2458661/Nominated by patients and colleagues, recipients of the first annual National Psoriasis Foundation Medical Professionals Awards exemplify the outstanding work being done in the psoriatic disease
- FDA Awards Tentative Approval for Zenavod to Treat Rosaceahttps://practicaldermatology.com/news/fda-awards-tentative-approval-for-zenavod-to-treat-rosacea/2458711/The FDA awarded Dr. Reddy's Laboratories tentative approval for Zenavod™ (doxycycline) Capsules, 40mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Promius™ Pharma, LLC, t